Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a diabetes drug tame asthma in obesity?

NCT ID NCT05254314

First seen Mar 14, 2026 · Last updated May 25, 2026 · Updated 8 times

Summary

This study tests whether semaglutide, a drug already approved for diabetes and weight loss, can improve asthma control and reduce airway inflammation in adults with obesity who still have asthma symptoms despite using inhaled steroids. About 100 participants will receive either semaglutide or a placebo for up to 24 weeks. The goal is to see if the drug helps both asthma and weight, offering a new treatment option for obesity-related asthma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.